Amylyx Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
AMLX$30.91+2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of January 1, 2024 | 67,707,432 | $7 | $738,177 | $197 | $(304,949) | $433,432 |
| Issuance of common stock upon exercise of stock options | 210,088 | — | 327 | — | — | 327 |
| Issuance of common stock upon vesting of RSUs | 712,218 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 33,038 | — | — | 33,038 |
| Other comprehensive loss | — | — | — | (289) | — | (289) |
| Net loss | — | — | — | — | (301,743) | (301,743) |
| Balance as of December 31, 2024 | 68,629,738 | $7 | $771,542 | $(92) | $(606,692) | $164,765 |
| Issuance of common stock upon financing, net of issuance costs | 39,839,285 | 4 | $256,310 | $— | $— | $256,314 |
| Issuance of common stock upon exercise of stock options | 213,090 | — | 774 | — | — | 774 |
| Issuance of common stock upon vesting of RSUs | 1,202,389 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 27,645 | — | — | 27,645 |
| Other comprehensive income | — | — | — | 496 | — | 496 |
| Net loss | — | — | — | — | (144,735) | (144,735) |
| Balance as of December 31, 2025 | 109,884,502 | $11 | $1,056,271 | $404 | $(751,427) | $305,259 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.